German drugmaker Vibalogics said it will invest $150 million to expand a 110,000-square foot virotherapy manufacturing plant in Boston.

The company, which produces viruses that kill cancer cells, viral vector vaccines and viral vector gene therapies, expects the upgraded site to be operational by the second half of 2021.

“Boston is the largest global hub for cell and gene therapy R&D, so there is also a great pool of local talent and expertise to draw from,” said Vibalogics CEO Tom Hochuli.